Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide ...

This platform aims to deliver high-quality cyclic peptides with faster timelines and better economy across a broad range of ...

Cyclic peptides often exhibit low membrane permeability which can be significantly improved via amide-to-ester substitutions—as demonstrated by researchers from Tokyo Institute of Technology ...

When tested on rats, the peptides showed oral bioavailability up to 18%, which means that when the cyclic peptide drug is taken orally, 18% of it successfully enters the bloodstream and to have a ...

A cyclic peptide is a type of organic molecule that consists of amino acids linked together in a circular or lariat shape. What makes them particularly attractive is that they can target ...

The potential of cyclic peptides in drug discovery has become increasingly apparent in recent years. Their cyclic structure imbues them with enhanced target affinity, metabolic stability and a ...

Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time ...

Cyclic peptides, which combine characteristics of both small molecules and proteins, have emerged as significant molecules for regulating protein–protein interactions (PPIs).

Nearly 24 cyclic peptides have received clinical approval since 2000 to treat diseases from cancer and lupus, but many of them need modification in order to enter cells in sufficient quantities.

Scientists were able to synthesize 8,448 cyclic peptides, proving it can deliver orally available peptides against a given target. Orbis is keeping mum on specific disease targets for now.

SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and ...